Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections-Reference-Cited by-同舟云学术

Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections

Published:2019-07 Issue:7 Volume:31 Page:845-852
ISSN:0954-691X
Container-title:European Journal of Gastroenterology & Hepatology
language:en
Short-container-title:

Author:

Koukoulioti Eleni,Brodzinski Annika,Mihm Ulrike,Sarrazin Christoph,Jung Maria-Christina,Schott Eckart,Fülöp Balazs,Schlosser Beate,Berg Thomas,van Bömmel Florian

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference37 articles.

1. Lamivudine for patients with chronic hepatitis B and advanced liver disease;Liaw;N Engl J Med,2004

2. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection;Hosaka;Hepatology,2013

3. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years;Hadziyannis;Gastroenterology,2006

4. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study;Marcellin;Lancet,2013

5. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years;Fasano;J Hepatol,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments;Gastrointestinal Disorders;2024-09-12

2. High Frequency of Antiviral Resistance Mutations in HBV Genotypes A2 and H: Multidrug Resistance Strains in Mexico;Journal of Clinical and Translational Hepatology;2023-06-07

3. “Elimination of Hepatitis by 2030”: Present Realities and Future Projections;Infectious Diseases & Immunity;2021-11-17

4. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical;Exploration of Medicine;2021-09-29

5. Anti‐hepatitis B virus activity and hepatoprotective effect of des(rhamnosyl) verbascoside from Lindernia ruellioides in vitro;Phytotherapy Research;2021-06-19